GSK & Yale Team up for Drug Discovery

GSK and Yale will work together to develop an entirely new class of drugs based on PROTACs technology.

GlaxoSmithKline (GSK) and Yale University have announced a new collaboration to design a potential new class of medicines.

The research collaboration will centre around proteolysis targeting chimeric molecules (PROTACs), which scientists believe can be turned into medicines that degrade disease-causing proteins.

Researchers at Yale have designed these molecules so that they bind disease-causing proteins and direct them to the cell's housecleaning machinery, where they are degraded.

GSK will have the opportunity to license suitable drug candidates based on this technology across all therapy areas, with the university being eligible for milestone and royalty payments on any drugs that are discove